The main objective of this study is: * to establish etiology of acute aseptic meningitis/meningoencephalitis in Slovenia * to assess the clinical course and outcome of tick-borne encephalitis and Lyme neuroborreliosis * to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with tick-borne encephalitis and Lyme neuroborreliosis
Study Type
OBSERVATIONAL
Enrollment
800
patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia
Ljubljana, Slovenia
RECRUITINGUMC Ljubljana, Department of Infectious Diseases
Ljubljana, Slovenia
RECRUITINGChanges in selected clinical parameters in patients with acute aseptic meningitis/meningoencephalitis
Selected clinical parameters (presence or absence of headache, nausea, vomiting, neurologic symptoms, maximal temperature, etc) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and at follow-up visits: on day 7 or on day of discharge from hospital, on day 14, at 2, 6, and 12 months.
Time frame: at enrollment and during 12 months follow-up
Changes in selected laboratory parameters in patients with acute aseptic meningitis/meningoencephalitis
Selected laboratory parameters (complete blood count, biochemistry test results) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and at follow-up visits: on day 7 or on day of discharge from hospital, on day 14, at 2, 6, and 12 months.
Time frame: at enrollment and during 12 months follow-up
Changes in selected microbiologic parameters in patients with acute aseptic meningitis/meningoencephalitis
Selected microbiologic parameters (anti Borrelia burgdorferi immunoglobulin M and G in serum and cerebrospinal fluid results, polymerase chain reaction for enteroviruses, herpes simplex virus type 1 and 2 in cerebrospinal fluid results) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and anti Borrelia burgdorferi immunoglobulin M and G in serum at follow-up visits: at 2, 6, and 12 months.
Time frame: at enrollment and during 12 months follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.